Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria


Cite item

Full Text

Abstract

Selective inhibitors of sodium-glucose cotransporter belong to a new class of drugs for the treatment of type 2 diabetes mellitus. The mechanism of their action is based on insulin-independent reduction of glucose reabsorption in the proximal renal tubules, which leads to stimulation of its excretion in the urine and, accordingly, to a decrease in the concentration of glucose in the blood plasma. Drugs of this group demonstrate effectiveness in the treatment of type 2 diabetes, but their use may be associated with an increased frequency of urinary tract infections. Pharmacological glucosuria, which leads to a decrease in the concentration of glucose in the blood, creates the preconditions for the occurrence of urinary tract infections. Urinary tract and genital infections are the most common adverse events associated with the use of sodium-glucose cotransporter inhibitors. In the presented literature review for 2016–2019, the relationship between urinary tract infections in patients with type 2 diabetes mellitus and therapy with sodium-glucose cotransporter inhibitors was analyzed.

About the authors

N. V. Sturov

People’s Friendship University of Russia

Author for correspondence.
Email: servit77@yandex.ru
ORCID iD: 0000-0002-3138-8410

к.м.н., доц., зав. каф. общей врачебной практики, зам. дир. по учебной работе Медицинского института

Russian Federation, Moscow

S. V. Popov

People’s Friendship University of Russia; Central Clinical Hospital of St. Alexy of the Moscow Patriarchate

Email: servit77@yandex.ru
ORCID iD: 0000-0002-0567-4616

д.м.н., проф. каф. общей врачебной практики Медицинского института; врач-уролог

Russian Federation, Moscow

N. K. Mamporia

Central Clinical Hospital of St. Alexy of the Moscow Patriarchate

Email: servit77@yandex.ru
ORCID iD: 0000-0003-2243-1365

врач-терапевт

Russian Federation, Moscow

A. A. Mager

People’s Friendship University of Russia

Email: servit77@yandex.ru
ORCID iD: 0000-0003-4308-5262

клинический ординатор каф. урологии и оперативной нефрологии с курсом онкоурологии, каф. общей врачебной практики Медицинского института

Russian Federation, Moscow

References

  1. Figueiredo IR, Rose SCP, Freire NB, et al. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review. Rev Assoc Med Bras. 1992. 2019 Feb;65(2):246-52. doi: 10.1590/1806-9282.65.2.246
  2. Kushner P. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes. Womens Health (Lond). 2016;12(3):379-88. doi: 10.2217/whe-2016-0001
  3. Rizzi M, Trevisan R. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutr Metab Cardiovasc Dis. 2016;26(11):963-70. doi: 10.1016/j.numecd.2016.07.006
  4. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. doi: 10.1038/s41598-017-02733-w
  5. Shestakova MV, Wilding JPH, Wilpshaar W, et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:240-50. doi: 10.1016/j.diabres.2018.10.018
  6. Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812-9. doi: 10.1111/dom.12684
  7. Terauchi Y, Tamura M, Senda M, et al. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017;19(10):1397-407. doi: 10.1111/dom.12957
  8. Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. J Am Geriatr Soc. 2016;64(3):543-52. doi: 10.1111/jgs.14028
  9. Qiu R, Balis D, Xie J, et al. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-62. doi: 10.1080/03007995.2016.1271780
  10. Storgaard H, Gluud LL, Bennett C, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125
  11. Trujillo JM, Nuffer WA. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy. 2017;37(4):481-91. doi: 10.1002/phar.1903
  12. Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. Int J Clin Pract. 2017;71(5):e12937. doi: 10.1111/ijcp.12937
  13. Donnan JR, Grandy CA, Chibrikov E, et al. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. CMAJ Open. 2018;6(4):E594-E602. doi: 10.9778/cmajo.20180111
  14. Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-55. doi: 10.1111/dom.12825
  15. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783-94. doi: 10.1111/dom.12670
  16. Jabbour S, Seufert J, Scheen A, et al. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018 Mar;20(3):620-8. doi: 10.1111/dom.13124
  17. Feng M, Lv H, Xu X, et al. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(30):e16575. doi: 10.1097/MD.0000000000016575
  18. Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503-14. doi: 10.1007/s00592-018-1116-0
  19. Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019 May – Jun;13(3):2001-8. doi: 10.1016/j.dsx.2019.04.035
  20. Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016 Jun;38(6):1299-313. doi: 10.1016/j.clinthera.2016.03.031
  21. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2
  22. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295-311. doi: 10.1080/14740338.2019.1602116
  23. Esteban-Jiménez O, Navarro-Pemán C, Urieta-González L. Seguridad de los iSGLT-2. Revisión de las reacciones adversas notificadas a nivel nacional [Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database]. Semergen. 2018;44(1):23-9. doi: 10.1016/j.semerg.2017.10.003
  24. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med. 2016;128(4):409-17. doi: 10.1080/00325481.2016.1167570
  25. Yang L, Zhang L, He H, et al. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Ther. 2019 Oct;10(5):1921-34. doi: 10.1007/s13300-019-0674-7
  26. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res Clin Pract. 2017;130:180-5. doi: 10.1016/j.diabres.2017.06.018
  27. BersoffMatcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019 Jun 4;170(11):764-9. doi: 10.7326/M19-0085

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Mechanism of action of SGLT2 inhibitors

Download (186KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies